RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia

Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS‐ALL) is characterized by high frequency of CRLF2‐rearrangements, JAK2‐mutations, or RAS‐pathway mutations. Intrigui...

Descripción completa

Detalles Bibliográficos
Autores principales: Koschut, David, Ray, Debleena, Li, Zhenhua, Giarin, Emanuela, Groet, Jürgen, Alić, Ivan, Kham, Shirley Kow-Yin, Chng, Wee Joo, Ariffin, Hany, Weinstock, David M., Yeoh, Allen Eng-Juh, Basso, Giuseppe, Nižetić, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843419/
https://www.ncbi.nlm.nih.gov/pubmed/33247204
http://dx.doi.org/10.1038/s41388-020-01567-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843419/
https://www.ncbi.nlm.nih.gov/pubmed/33247204
http://dx.doi.org/10.1038/s41388-020-01567-7

Ejemplares similares